Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Covetrus, Inc.    CVET

COVETRUS, INC.

(CVET)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

COVETRUS, INC. : Regulation FD Disclosure (form 8-K)

09/09/2020 | 04:49pm EST

Item 7.01. Regulation FD Disclosure.

On September 9, 2020, Covetrus, Inc. (the "Company") converted a portion of its 7.50% Series A Convertible Preferred Stock, par value $0.01 per share (the "Preferred Stock"), issued to CD&R VFC Holdings, L.P. (the "Investor"), an affiliate of Clayton, Dubilier & Rice, LLC, on May 19, 2020. In connection with such conversion, the Company issued approximately 14.4 million shares of its common stock, par value $0.01 per share (the "Common Stock"), to the Investor, which, together with the shares of Common Stock previously owned by the Investor, results in the Investor owning approximately 19.99% of the Company's outstanding shares of Common Stock. Following such conversion, the Investor will continue to own shares of Preferred Stock that are convertible into approximately 8.2 million shares of Common Stock (as may be adjusted pursuant to the terms governing the Preferred Stock).

The conversion of such shares of Preferred Stock on September 9, 2020 will result in a reduction to the Company's cash dividend payments on the Preferred Stock by approximately $12.0 million on an annualized basis. The Company may convert additional shares of Preferred Stock into shares of Common Stock so long as the Investor will not own shares of Common Stock in excess of 19.99% of the Company's outstanding shares of Common Stock, and the Company expects to seek shareholder approval to convert any remaining shares of Preferred Stock into shares of Common Stock no later than at its next annual meeting of shareholders. The conversion of the remaining shares of Preferred Stock into shares of Common Stock, assuming shareholder approval is obtained, will result in an additional reduction to the Company's cash dividend payments on the Preferred Stock by approximately $6.8 million on an annualized basis.

The information in this Item 7.01 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward-Looking Statements

This report contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may, in some cases use terms such as "predicts," "believes," "potential," "continue," "anticipates," "estimates," "expects," "plans," "intends," "may," "could," "might," "likely," "will," "should" or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous risks and uncertainties, and actual results could differ materially from those anticipated due to a number of factors including, but not limited to, the Company's ability to convert the shares of Preferred Stock and realize the cash dividend savings and the Company's ability to obtain shareholder approval for the conversion of the remaining shares of Preferred Stock. Our forward-looking statements are based on current beliefs and expectations of our management team and, except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this report or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Investors are cautioned not to place undue reliance on these forward-looking statements.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about COVETRUS, INC.
11/18COVETRUS, INC. : Submission of Matters to a Vote of Security Holders, Regulation..
AQ
11/10COVETRUS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
11/10COVETRUS : 3Q Earnings Snapshot
AQ
11/10COVETRUS, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
11/10COVETRUS : Announces Financial Results for Third Quarter of 2020
AQ
11/10Covetrus Announces Financial Results for Third Quarter of 2020
GL
10/27COVETRUS : Announces Third Quarter 2020 Earnings Release Date and Conference Cal..
AQ
10/27Covetrus Announces Third Quarter 2020 Earnings Release Date and Conference Ca..
GL
10/09COVETRUS : Makes a Strategic Investment in Veterinary Study Groups, the Premier ..
BU
09/28COVETRUS : Holds Virtual VetSummit Conference - October 16-18
BU
More news
Financials (USD)
Sales 2020 4 272 M - -
Net income 2020 -23,0 M - -
Net Debt 2020 675 M - -
P/E ratio 2020 -111x
Yield 2020 -
Capitalization 3 391 M 3 391 M -
EV / Sales 2020 0,95x
EV / Sales 2021 0,88x
Nbr of Employees 5 300
Free-Float 72,5%
Chart COVETRUS, INC.
Duration : Period :
Covetrus, Inc. Technical Analysis Chart | CVET | US22304C1009 | MarketScreener
Technical analysis trends COVETRUS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 27,00 $
Last Close Price 26,59 $
Spread / Highest target 16,6%
Spread / Average Target 1,54%
Spread / Lowest Target -24,8%
EPS Revisions
Managers
NameTitle
Benjamin C. Wolin President, Chief Executive Officer & Director
Philip A. Laskaway Chairman
Matthew J. Foulston Chief Financial Officer
Georgina Wraight President-Global Technology Solutions & EVP
Steve Palmucci Global Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
COVETRUS, INC.101.44%3 391
ABBOTT LABORATORIES22.51%188 597
MEDTRONIC PLC-0.12%151 957
BECTON, DICKINSON AND COMPANY-16.36%65 936
HOYA CORPORATION32.49%48 567
BAXTER INTERNATIONAL INC.-9.84%38 511